Comparative antiplatelet activity of COX1 NSAIDS versus aspirin, encompassing regimen simplification and gastroprotection: a call for a controlled study.

Comparative antiplatelet activity of COX1 NSAIDS versus aspirin, encompassing regimen simplification and gastroprotection: a call for a controlled study.

Rothschild B M

Reumatismo

2004

2004-06

This study was conducted to assess the feasibility of COX1 NSAID substitution for aspirin for preventative therapy related to circulating anticoagulants, as manifest by inhibition of platelet aggregation. There was no difference in platelet aggregation inhibition between aspirin, naproxen, ketoprofen or diclofenac and misoprostol (in combination in the form of Arthrotec). As COX1 NSAIDs appear equivalent in platelet inhibition efficacy to aspirin, therapeutic regimens can be simplified in those individuals who require an NSAID for other problems. Further, despite its short serum halflife, Arthrotec appears as effective as an antiplatelet agent. Controlled, double blind studies of efficacy in blocking clinical events (both cardiovascular and gastrointestinal) are recommended.

Female; Humans; Male; Middle Aged; Time Factors; Feasibility Studies; Anti-Inflammatory Agents; Drug Combinations; Aspirin/administration & dosage/adverse effects/*therapeutic use; Cyclooxygenase Inhibitors/administration & dosage/adverse effects/*therapeutic use; Diclofenac/administration & dosage/adverse effects/*therapeutic use; Ketoprofen/administration & dosage/adverse effects/therapeutic use; Misoprostol/administration & dosage/adverse effects/*therapeutic use; Naproxen/administration & dosage/adverse effects/therapeutic use; Platelet Aggregation Inhibitors/administration & dosage/adverse effects/*therapeutic use; Stomach/drug effects; Non-Steroidal/administration & dosage/adverse effects/*therapeutic use

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

89–93

2

56